CarcinogenesisSETD2 as a regulator of N6-methyladenosine RNA methylation and modifiers in cancerKumari, Subhadra; Muthusamy, SrinivasanAuthor Information Department of Life Science, National Institute of Technology, Rourkela, India Received 16 October 2019 Accepted 18 February 2020 Correspondence to Dr. Srinivasan Muthusamy, Department of Life Sciences, Human Molecular Genetics Lab (Room no MC227), National Institute of Technology, Rourkela - 769008, Odisha, India, E-mail: email@example.com European Journal of Cancer Prevention: November 2020 - Volume 29 - Issue 6 - p 556-564 doi: 10.1097/CEJ.0000000000000587 Buy Metrics Abstract Cancer is an unpleasant, painful disease. It is one of the most devastating diseases worldwide diminishing many lives. Many genetic and epigenetic changes occur before cancer develops. Mutation in SETD2 gene is one such example. RNA splicing, DNA damage repair, DNA methylation and histone methylation are some of the biological processes mediated by SETD2. SETD2 (histone H3 lysine 36 methyltransferase) is a frequently mutated gene in different types of cancer. Loss of SETD2 is associated with worse prognosis and aggressive phenotypes. Histone modification is one of the epigenetic regulation having a significant effect on gene regulation. N6-methyladenosine (m6A) mRNA modification is a well-known posttranscriptional modification playing a pivotal role in many normal and pathological processes affecting RNA metabolism. SETD2 catalyses H3K36 trimethylation and in turn H3K36me3 guides the deposition of m6A on nascent RNA transcripts. Finally, this review summarizes the deep understanding of the role of SETD2 in RNA methylation/modification and how SETD2 mutation contributes to tumour development. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.